Advancements in dry powder delivery to the lung.
The dry powder inhaler (DPI) has become widely known as a very attractive platform for drug delivery. Many patients have traditionally used DPIs to treat asthma and chronic obstructive pulmonary disease. Recently, the development of new DPIs for delivering therapeutic proteins such as insulin has been accelerated by patient demands, and innovative research. The current market for DPIs has over 20 devices presently in use, and many devices under development for delivering a variety of therapeutic agents. DPIs are recognized as suitable alternatives to pressurized metered dose inhalers for some patients, but the performance of DPI devices may vary according to a given patient's physiological condition. This variation can be associated with the necessary powder dispersion mechanism of each device. As such, much interest has focused on the development of efficient powder dispersion mechanisms, as this effectively minimizes the influence of interpatient variability. This article reviews DPI devices currently available, advantages of newly developed devices, outlines some requirements for future device design.
Son
Yoen-Ju
YJ
College of Pharmacy, University of Texas at Austin, Austin, TX 78712, USA.
McConville
Jason T
JT
D002626:Chemistry, Pharmaceutical; D006801:Humans; D008168:Lung / Q000378:metabolism*; D009330:Nebulizers and Vaporizers; D010349:Patient Compliance; D011208:Powders / Q000737:chemistry*
D011208:Powders